Description
Venetoclax, marketed under the brand name VENCLEXTA, It is an prescription medication that has been approved venetoclax (Venclexta) for multiple uses at different times:
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
On May 15, 2019, the FDA approved venetoclax in combination with obinutuzumab (Gazyva) for the initial treatment of adults with CLL or SLL.
Acute myeloid leukemia (AML)
On October 16, 2020, the FDA approved venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for adults with newly-diagnosed AML who are 75 years or older or have comorbidities that preclude intensive induction chemotherapy. The FDA previously granted accelerated approval for venetoclax for this indication in November 2018.
What is VENCLEXTA (venetoclax) ?
VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
CLL/SLL
In the US, venetoclax is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Indication does not depend on mutation status (e. g. 17p deletion, IGHV mutation, 12+). In the EU, venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adults who are unsuitable for or have failed a B cell receptor pathway inhibitor and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adults who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor.
Other types of leukemia
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). For this purpose it is with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
How to order approved “VENCLEXTA (venetoclax) for tablets” Medicine?
VENCLEXTA (Venetoclax) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing VENCLEXTA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
